Denmark’s Sunstone Life Science Ventures has invested five million euros ($5.6 million) out of its LifeScience VenturesFund IV into Forendo Pharma, a Finnish clinical-stage drug development company focusing on novel treatments in women's health.
The investment is designated to finance the continuation of Forendo’s positive Phase Ia study in post-menopausal women into Phase Ib in pre-menopausal women, and later Phase II for the treatment of endometriosis.
In March 2019, Forendo successfully completed a Phase Ia study of its lead program FOR-6219, a novel oral formulation of a tissue specific treatment of endometriosis. FOR-6219 was found to be safe and well tolerated. Endometriosis is a chronic condition affecting up to 10% of women in the reproductive age and causes recurring pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have limitations in efficacy or cause harmful side effects due to estrogen depletion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze